Stocktoria

GILEAD SCIENCES, INC. GILD

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1992-01-22 · LEI

GILEAD SCIENCES, INC. statistics & valuation

Market cap$158.8B
P / E18.7×
P / S5.4×
P / B7.0×
P / FCF16.8×
Dividend yield2.52%
Net margin28.9%
Return on equity37.5%
FCF margin32.1%
Net debt$24.9B
Net debt / EBITDA2.4×
Enterprise value USD$183.7B
EV / EBITDA17.7×
Earnings yield EBIT/EV5.5%
Return on capital21.2%
Graham number -61.3%$52.53

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($52.53); a green figure means the price is below it.

Profitability & efficiency

Net margin (%)
44.40% 17.70% 24.70% 24.00% 0.50% 22.80% 16.80% 20.90% 1.70% 28.90% 2016201720182019202020212022202320242025
Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
58.00% 54.10% 37.10% 19.10% 16.50% 36.30% 26.90% 28.00% 5.80% 34.00% 2016201720182019202020212022202320242025
Return on equity (%)
69.70% 22.60% 25.30% 23.80% 0.70% 29.50% 21.60% 24.80% 2.50% 37.50% 2016201720182019202020212022202320242025
Shares outstanding
1.36B 1.32B 1.31B 1.28B 1.26B 1.26B 1.26B 1.26B 1.25B 1.25B 2016201720182019202020212022202320242025
Net debt ($)
$18.12B $25.95B $6.63B $10.46B $25.41B $21.36B $19.82B $24.99B $26.71B $24.94B 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
23.70% 6.60% 8.60% 8.70% 0.20% 9.20% 7.30% 9.10% 0.80% 14.40% 2016201720182019202020212022202320242025
Free cash flow margin (%)
33.80% 37.10% 30.50% 39.60% 30.60% 27.40% 35.80% 32.10% 2016201720182019202020212022202320242025
Debt / equity (×)
1.36× 1.64× 1.14× 0.98× 1.72× 1.27× 1.19× 1.09× 1.38× 1.10× 2016201720182019202020212022202320242025
EPS ($)
$9.94 $3.51 $4.17 $4.22 $0.10 $4.93 $3.64 $4.50 $0.38 $6.78 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

P / E vs its own history

GILEAD SCIENCES, INC. trades at about 20× earnings — near its 10-year norm (10-year range 7.3×–656×, median 20.9×).

7.3× 656×

Shaded band = 10-year range (7.3×–656×); dot = today's 20×.

Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating margin34.0%5.8%28.0%26.9%36.3%16.5%19.1%37.1%54.1%58.0%
Net margin28.9%1.7%20.9%16.8%22.8%0.5%24.0%24.7%17.7%44.4%
FCF margin32.1%35.8%27.4%30.6%39.6%30.5%37.1%33.8%——
Return on assets14.4%0.8%9.1%7.3%9.2%0.2%8.7%8.6%6.6%23.7%
Return on equity37.5%2.5%24.8%21.6%29.5%0.7%23.8%25.3%22.6%69.7%
Debt / equity1.10×1.38×1.09×1.19×1.27×1.72×0.98×1.14×1.64×1.36×
Current ratio1.551.601.431.291.271.403.103.382.742.12

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.